Key Highlights
- Net loss per share was USD 0.36 against an estimate of USD -0.41, and the company reported no revenue.
- Net loss was USD 17.85 million against USD 14.70 million, with Research and Development expenses of USD 15.06 million.
- Cash, cash equivalents and marketable securities were USD 163.3 million, against an accumulated Deficit of USD 262.6 million.
- Investigational New Drug applications for OKI-345 and OKI-355 are planned for the first half of 2027.
OnKure Therapeutics, Inc. (NASDAQ:OKUR) reported its third quarter against the backdrop of a USD 150.0 million private Placement completed in March 2026 and a larger at-the-market sales agreement filed in August. Net loss per share was USD 0.36, against an estimate of USD -0.41, and the clinical-stage company reported no revenue. Its two programs, OKI-345 in breast cancer and OKI-355 in vascular anomalies, are scheduled for Investigational New Drug submissions in the first half of 2027.
How the Financing Fits the Quarter
The 2026 private placement raised aggregate gross proceeds of approximately USD 150.0 million. The company issued 26,713,638 shares of common stock and pre-funded warrants for 9,430,957 shares, and agreed to use the proceeds for research and development in its vascular anomalies and breast cancer programs, excluding the former lead candidate OKI-219, and for working capital.
In August 2026, the company filed a prospectus supplement raising the amount of common stock that may be sold under its at-the-market agreement to up to USD 100.0 million. No shares had been sold under that agreement as of September 30. The company said more cash available to invest produced higher interest income, and it described its cash resources as sufficient to fund planned operations for at least 12 months from the issuance date of its quarterly financial statements.
Results Around the Placement
Research and development expenses were USD 15.06 million against USD 11.92 million, which the company attributed to USD 1.5 million more outsourced preclinical work, USD 1.2 million more Manufacturing costs and USD 0.3 million more consulting. General and administrative expenses were USD 4.29 million against USD 3.59 million, with USD 0.4 million more personnel costs and USD 0.2 million more consulting fees.
Total operating expenses were USD 19.35 million against USD 15.50 million. Interest income was USD 1.51 million against USD 0.80 million. Net loss was USD 17.85 million against USD 14.70 million, and net loss per share was USD 0.36 against USD 1.09 in the third quarter of 2025.
Over nine months, net loss was USD 48.35 million against USD 46.01 million, operating expenses were USD 51.87 million and cash used in Operating Activities was USD 36.37 million.
Cash, Funding Needs and Programs
Cash, cash equivalents and marketable securities were USD 163.3 million at September 30. The company has not generated product Revenue and stated that it needs additional capital, which it may seek through Equity or debt financings, collaborations or licensing. It also projects 2026 general and administrative expenses and other income above 2025 levels.
OKI-345 and OKI-355 are designed to selectively inhibit mutant PI3Kα while sparing the wild-type protein, which the company said could widen the therapeutic index. The company focuses its resources on these two candidates and its research programs.
Balance Sheet and Cash Markers
Cash and marketable securities of USD 163.3 million sit alongside a third quarter net loss of USD 17.85 million, nine-month cash used in operations of USD 36.37 million and an accumulated deficit of USD 262.6 million. The USD 100.0 million at-the-market ceiling compares with no shares sold under it at quarter end.
Management named a small set of dated items: Investigational New Drug applications for OKI-345 and OKI-355 in the first half of 2027, the continuing use of private placement proceeds for the breast cancer and vascular anomalies programs, and the at-the-market agreement that remains available. Its stated priority is advancing the two PI3Kα pan-mutant candidates toward the clinic.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...